DE3676187D1 - Die ribosome inhibierende, mittels oxidation und bildung von schiffbasen modifizierte glukoproteine, verfahren zur herstellung derselben und ein solches glukoprotein enthaltende immunotoxine. - Google Patents

Die ribosome inhibierende, mittels oxidation und bildung von schiffbasen modifizierte glukoproteine, verfahren zur herstellung derselben und ein solches glukoprotein enthaltende immunotoxine.

Info

Publication number
DE3676187D1
DE3676187D1 DE8686402812T DE3676187T DE3676187D1 DE 3676187 D1 DE3676187 D1 DE 3676187D1 DE 8686402812 T DE8686402812 T DE 8686402812T DE 3676187 T DE3676187 T DE 3676187T DE 3676187 D1 DE3676187 D1 DE 3676187D1
Authority
DE
Germany
Prior art keywords
shipbase
glucoproteins
glucoprotein
mexico
ribosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686402812T
Other languages
English (en)
Inventor
Pierre Casellas
Bernard Bourrie
Xavier Canat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8518981A external-priority patent/FR2591894B1/fr
Priority claimed from FR8611643A external-priority patent/FR2602682B1/fr
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of DE3676187D1 publication Critical patent/DE3676187D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DE8686402812T 1985-12-20 1986-12-16 Die ribosome inhibierende, mittels oxidation und bildung von schiffbasen modifizierte glukoproteine, verfahren zur herstellung derselben und ein solches glukoprotein enthaltende immunotoxine. Expired - Fee Related DE3676187D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8518981A FR2591894B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
FR8611643A FR2602682B1 (fr) 1986-08-12 1986-08-12 Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff

Publications (1)

Publication Number Publication Date
DE3676187D1 true DE3676187D1 (de) 1991-01-24

Family

ID=26224905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686402812T Expired - Fee Related DE3676187D1 (de) 1985-12-20 1986-12-16 Die ribosome inhibierende, mittels oxidation und bildung von schiffbasen modifizierte glukoproteine, verfahren zur herstellung derselben und ein solches glukoprotein enthaltende immunotoxine.

Country Status (15)

Country Link
US (2) US4911911A (de)
EP (1) EP0234151B1 (de)
JP (1) JPH0742316B2 (de)
KR (1) KR950007215B1 (de)
AR (1) AR242958A1 (de)
AU (1) AU602320B2 (de)
CA (1) CA1276108C (de)
DE (1) DE3676187D1 (de)
DK (1) DK611886A (de)
ES (1) ES2020945B3 (de)
GR (1) GR3001597T3 (de)
IE (1) IE59649B1 (de)
IL (1) IL80972A (de)
NZ (1) NZ218705A (de)
PT (1) PT83946B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5258501A (en) * 1988-11-25 1993-11-02 Slobodan Barbaric Stabilization of glycoproteins
US5234905A (en) * 1991-02-22 1993-08-10 University Of Colorado Foundation, Inc. Soluble CD4 molecules modified to prolong circulating half-life
US5112607A (en) * 1991-06-05 1992-05-12 The United States Of America As Represented By The Secretary Of The Army Potentiation of immunotoxin action by Brefeldin A
SE503711C2 (sv) * 1994-12-14 1996-08-12 Medicarb Ab Flerstegsförfarande för beläggning av en intraokulär lins
US5891506A (en) * 1996-08-09 1999-04-06 Medtronic, Inc. Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices
JP2009508938A (ja) * 2005-09-22 2009-03-05 ハダシット メディカル リサーチ サーヴィスィズ アンド ディベロップメント リミテッド 治療上活性な化合物の結合体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
CA1083508A (fr) * 1975-11-13 1980-08-12 Jacques Grange Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique
US4154726A (en) * 1978-03-20 1979-05-15 Standard Oil Company (Indiana) Process for modifying the cell wall of single-cell microorganisms using periodate ions
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain

Also Published As

Publication number Publication date
US5104976A (en) 1992-04-14
IL80972A0 (en) 1987-03-31
GR3001597T3 (en) 1992-11-23
KR870006086A (ko) 1987-07-09
US4911911A (en) 1990-03-27
PT83946B (pt) 1989-05-12
AU602320B2 (en) 1990-10-11
AU6663086A (en) 1987-06-25
JPS62167800A (ja) 1987-07-24
IE59649B1 (en) 1994-03-09
PT83946A (fr) 1987-01-01
JPH0742316B2 (ja) 1995-05-10
KR950007215B1 (ko) 1995-07-04
NZ218705A (en) 1989-10-27
EP0234151B1 (de) 1990-12-12
IL80972A (en) 1992-08-18
DK611886D0 (da) 1986-12-18
DK611886A (da) 1987-06-21
ES2020945B3 (es) 1991-10-16
IE863305L (en) 1987-06-20
EP0234151A1 (de) 1987-09-02
CA1276108C (en) 1990-11-13
AR242958A1 (es) 1993-06-30

Similar Documents

Publication Publication Date Title
DE3677248D1 (de) Bimodale silikonemulsionen, verfahren zur herstellung von silikonemulsionen und die so erhaltenen emulsionen.
DE3684742D1 (de) Verfahren zur herstellung von loetmetallen.
DE3784841D1 (de) Konfektprodukt und verfahren zur herstellung.
DE3580892D1 (de) Dichtungselement fuer die hoehlung des knochenmarks und verfahren zu dessen herstellung.
DE3677044D1 (de) Verfahren zur herstellung von emulsionen und die so erhaltenen emulsionen.
DE3670859D1 (de) Verfahren zur herstellung von organophiler kieselsaeure.
DE3675687D1 (de) Verfahren zur herstellung von 2,2,6,6,-tetraalkyl-4-piperidylamine.
DE3673291D1 (de) Verfahren zur herstellung von polyvinylpyrrolidon.
DE3683728D1 (de) Verfahren zur herstellung von oxiracetam.
DE3586887D1 (de) Verfahren zur herstellung von basisschmieroelen und so erhaltene basisschmieroele.
DE3686064D1 (de) Verfahren zur herstellung farbstarker pigmente.
DE3681966D1 (de) Oxydationskatalysatoren der perovskitgruppe und verfahren zur herstellung.
DE3684541D1 (de) Verfahren zur herstellung von polyarylensulfiden.
DE3677272D1 (de) Verfahren zur herstellung von 2,2,6,6-tetraalkyl-4-piperidylaminen.
DE3667167D1 (de) Verfahren zur herstellung von 1,5-diazido-3-nitrazapentan.
DE3676215D1 (de) Verfahren zur herstellung von 2,3,4,5-tetrafluorbenzoesaeure.
DE3680454D1 (de) Verfahren zur herstellung von halogenhaltigen (2,2)-paracyclophanen.
DE3684569D1 (de) Verfahren zur herstellung von polyarylensulfid.
DE3674055D1 (de) Verfahren zur herstellung von 1,3,5-triazintrionen.
DE3685304D1 (de) Drucktuch und verfahren zur herstellung.
DE3676187D1 (de) Die ribosome inhibierende, mittels oxidation und bildung von schiffbasen modifizierte glukoproteine, verfahren zur herstellung derselben und ein solches glukoprotein enthaltende immunotoxine.
DE3685867D1 (de) Verfahren zur herstellung von selbstvernetzenden kationischen lackbindemitteln.
DE3675853D1 (de) Verfahren zur herstellung von polyarylensulfiden.
DE3673049D1 (de) Verfahren zur herstellung von 1,3-dialkyl-2-imidazolidinon.
DE3783199D1 (de) Verfahren zur herstellung von 4,4' diaminodiphenylmethan und derivaten davon.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee